Limitations, agreements, and source contact

NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours · Source last updated 2026-07-23

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee

false

restrictive Agreement

false

limitations And Caveats

description

Due to early termination of the study, a thorough evaluation of the safety and efficacy of the combination treatments could not be performed.

point Of Contact

email

info@nucana.com

organization

NuCana plc

phone

+44 131 357 1111

title

Medical and Scientific Affairs Department

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice